Novartis invests $3B to improve delivery of existing biologic drugs, enabling faster, easier injections.
Novartis has agreed to pay up to $3 billion to license Alteogen's Hybrozyme platform, which uses an enzyme to allow large biologic drugs to be absorbed faster via subcutaneous injections instead of long intravenous infusions. This innovation could im...
